SINGAPORE – Convergence has become a buzzword for firms running the gauntlet on clinical trials and drug approvals across Asia, signaling a growing acceptance that national regulators are more comfortable with a slow and steady pace to harmonization.
Multinational and domestic companies, of course, still want far more standardization in approval processes across the region, according to speakers...